Journey Medical Corp (DERM) Stock Price & Analysis
Journey Medical Corp (DERM) fell 5.93% to USD 6.19 as of July 26, 2026 at 18:17 UTC, according to Nexqual real-time market data.
DERM last closed at USD 6.58; the session ranged USD 6–6.67 on volume of 313,238 shares. Market capitalization is $170.44M, with a 52-week range of USD 4.31–9.56 (NCM). Source: Nexqual, July 26, 2026 at 18:17 UTC.
Key Statistics (as of July 26, 2026 at 18:17 UTC)
| Price | USD 6.19 |
|---|---|
| Change | ▼ 5.93% (down) |
| Previous Close | USD 6.58 |
| Open | USD 6.58 |
| Day Range | USD 6 – 6.67 |
| 52-Week Range | USD 4.31 – 9.56 |
| Volume | 313,238 shares |
| Market Cap | $170.44M |
| Exchange | NCM |
Technical Analysis (DERM)
Nexqual's technical model rates DERM "NEUTRAL" based on 3 bullish and 4 bearish signals across 125 daily candles, as of July 26, 2026 at 18:17 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 40.59 (neutral) |
| vs SMA50 | Below (USD 6.48) |
| MACD | 0.1 (positive) |
Analyst Ratings (DERM)
Wall Street analysts rate DERM "Strong Buy" based on 4 analysts, with a mean price target of USD 13.5 (range USD 12–16), per Nexqual as of July 26, 2026 at 18:17 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 4 |
| Mean Target | USD 13.5 |
| High Target | USD 16 |
| Low Target | USD 12 |
| Buy / Hold / Sell | 4 / 0 / 0 |
Earnings (DERM)
| Next Earnings Date | 2026-08-11 |
|---|---|
| Revenue Estimate | $18.37M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.08 vs est -0.09 ▲ beat |
| 2025-12-31 | USD -0.04 vs est -0.06 ▲ beat |
| 2025-09-30 | USD -0.09 vs est -0.04 ▼ miss |
| 2025-06-30 | USD -0.16 vs est -0.11 ▼ miss |
Source: Nexqual, July 26, 2026 at 18:17 UTC.
Financials & Fundamentals (DERM)
| Total Revenue | $64.68M |
|---|---|
| Revenue Growth (YoY) | +21.50% |
| Gross Margin | +65.44% |
| Operating Margin | -9.35% |
| Profit Margin | -14.82% |
| ROE | -36.62% |
| Debt / Equity | 82.6 |
| Current Ratio | 1.72 |
| Total Cash | $27.22M |
| Total Debt | $25.47M |
| Free Cash Flow | $-3.30M |
Source: Nexqual, July 26, 2026 at 18:17 UTC.
Financial Health Score (DERM)
Nexqual rates Journey Medical Corp's overall financial health "Mixed" across five dimensions, as of July 26, 2026 at 18:17 UTC.
| Growth | Solid — Revenue +10% YoY (annual) |
|---|---|
| Profitability | Solid — Gross margin 65%, operating -9% |
| Balance Sheet | Mixed — $27M cash vs $25M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$3M, burning cash |
| Efficiency | Critical — ROE -37%, ROA -4.5% |
Ownership (DERM)
| Insider Ownership | +32.77% |
|---|---|
| Institutional Ownership | +59.16% |
| Shares Outstanding | 21.53M |
| Float | 14.90M |
| Short % of Float | +20.13% |
Source: Nexqual, July 26, 2026 at 18:17 UTC.
Leadership (DERM)
Journey Medical Corp is led by Claude Maraoui (age 58), Founder, President, CEO & Director, per Nexqual as of July 26, 2026 at 18:17 UTC.
| Founder, President, CEO & Director | Claude Maraoui (age 58) |
|---|---|
| Executive Chairman | Lindsay Allan Rosenwald (age 70) |
| CFO & Corporate Controller | Joseph M. Benesch (age 58) |
| COO, General Counsel & Company Secretary | Ramsey Alloush (age 39) |
| Executive Director of Marketing | Brian Prout |
Major Backers & Investors (DERM)
Notable institutional backers of Journey Medical Corp include Wasatch Advisors LP, Tang Capital Management, LLC, WASATCH FUNDS TRUST-Wasatch Micro Cap Fund, according to Nexqual as of July 26, 2026 at 18:17 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Wasatch Advisors LP | 13.28% |
| Tang Capital Management, LLC | 7.48% |
| WASATCH FUNDS TRUST-Wasatch Micro Cap Fund | 7.15% |
| Opaleye Management Inc. | 4.46% |
| J. Goldman & Co., L.P. | 2.32% |
| Pale Fire Capital SE | 2.24% |
| UBS Group AG | 1.81% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 10.29% |
| BlackRock | 7.43% |
| Geode Capital | 2.15% |
Source: Nexqual, July 26, 2026 at 18:17 UTC.
From Journey Medical Corp's Latest SEC 10-K Filing (filed 2026-03-26)
Key Strengths & Strategy (as disclosed to the SEC)
- The Acquisition included two FDA-approved products (Amzeeq and Zilxi), and a development-stage dermatology program (FCD105), along with the Molecule Stabilizing Technology proprietary platform.
- The New Drug Application (the "NDA") was filed under Section 505(b)(2) of the Food Drug and Cosmetic Act ("FDCA") in January 2024 and was approved in November 2024 by the FDA.
- Amzeeq utilizes proprietary MST™ technology and is the first topical minocycline to be approved by the FDA for any condition.
- Intellectual Property General We rely on a combination of contractual provisions, confidentiality policies and procedures and patent, trademark, copyright and trade secrecy laws to protect the proprietary aspects of our technology and business.
Partnerships
- Each party may also terminate the Qbrexza APA for material breach by the other party. 13 Table of Contents As part of the Qbrexza APA, we were assigned an exclusive license agreement with Rose University ("Rose U") pursuant to which we obtained a worldwide exclusive license within a field of use including hyperhidrosis to practice, enforce and otherwise exploit certain patent rights, know-how and data related to Qbrexza.
- Pursuant to these agreements with Rose U and the related agreement with Stiefel with respect to Qbrexza, we are obligated to pay Rose U low-to-mid single-digit royalties on net product sales and low double-digit royalties on sublicense fees and certain milestone, royalty and other contingent payments received from sublicensees, to the extent such amounts are in excess of the milestone and royalty payments we are obligated to pay Rose U directly upon the events or sales triggering such payments.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| DBVT | DBV Technologies S.A. | USD 13.63 | ▲ 0% |
| TBPH | Theravance Biopharma, Inc. | USD 16.86 | ▲ 0.3% |
| CTMX | CytomX Therapeutics, Inc. | USD 3.24 | ▼ 2.7% |
| CLSDQ | Clearside Biomedical, Inc. | USD 0.25 | ▲ 0% |
| ACRS | Aclaris Therapeutics, Inc. | USD 5.23 | ▼ 6.94% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 26, 2026 at 18:17 UTC. This page is informational and not investment advice.